Tenderwize
Wróć do wyszukiwania

Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 186 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

15/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

15 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value, framework maximum, or lot values provided. Cannot estimate potential revenue.

Contract automatically ends upon patent expiry/loss of market exclusivity of Genvoya®. At that point, generic competiti...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of the pharmaceutical product Genvoya® (Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat) under discount agreements
  • Participation open to any pharmaceutical company that markets or intends to market Genvoya® in Germany
Pokaż pełne podsumowanie

Open House procedure by Techniker Krankenkasse (TK) and other German health insurers to conclude discount agreements under §130c SGB V for the active ingredient combination Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya®). The procedure allows any eligible pharmaceutical company to join at any time during the 24-month contract period (01.03.2025 – 28.02.2027). No negotiation on terms; standard conditions apply. No exclusivity. The notice indicates this is not a public procurement subject to EU directives but published voluntarily. Value not disclosed.

Ryzyka

No estimated value, framework maximum, or lot values provided. Cannot estimate potential revenue.

Contract automatically ends upon patent expiry/loss of market exclusivity of Genvoya®. At that point, generic competiti...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Participant must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
  • Must have a valid marketing authorization for Genvoya® or be otherwise entitled to place it on the market in Germany
  • Seat must be in Germany, EU/EEA

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria – all eligible participants are accepted.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

Single lot covering discount agreements for the fixed-dose combination Genvoya®. Contract duration max 24 months starting 01.03.2025, ends automatically at patent expiry or earlier.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Feb 2025 - Feb 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria – all eligible participants are accepted.

Termin

Deadline Feb 27, 2027

Szczegóły zamówienia

Data publikacji
20 Jan 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
41398-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3